Distinguishing essential thrombocythemia JAK2 V617F from polycythemia vera: limitations of erythrocyte values
- PMID: 30948488
- PMCID: PMC6821600
- DOI: 10.3324/haematol.2018.213108
Distinguishing essential thrombocythemia JAK2 V617F from polycythemia vera: limitations of erythrocyte values
Abstract
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV), but their sensitivity and specificity were not tested. Moreover, red cell values do not accurately predict red cell mass, which we use to discriminate essential thrombocythemia JAK2V617F from PV. Eighty-three PV and 39 essential thrombocythemia JAK2V617F patients were diagnosed based on JAK2V617F positivity, chromium-51 red cell mass, and marrow biopsy findings. Red cell values used to construct a receiver operating characteristic analysis determined optimal thresholds for distinguishing essential thrombocythemia JAK2V617F from PV. Red cell value frequencies were plotted determining if overlap existed. Chromium-51 red cell mass separated PV from essential thrombocythemia JAK2V617F, but red cell values overlapped in 25.0-54.7%. Our data indicate that a significant proportion of PV patients may be underdiagnosed by using only red cell values. A bone marrow biopsy was performed in 199 of 410 (48.5%) and a serum erythropoietin value was measured in 225 of 410 (54.9%) of potential PV patients at our institution. Without isotope studies, marrow biopsies and serum erythropoietin values should improve diagnostic accuracy and become mandatory, but clinical data suggest these tests have not been routinely performed. Therefore, the clinical hematologist must be aware of imperfect accuracy when using only red cell values for distinguishing essential thrombocythemia JAK2V617F from PV.
Copyright© 2019 Ferrata Storti Foundation.
Figures


Comment in
-
Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039. Haematologica. 2019. PMID: 31666340 Free PMC article. No abstract available.
Similar articles
-
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21. Pathol Biol (Paris). 2007. PMID: 16919893 Review.
-
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3. Am J Hematol. 2014. PMID: 24535932
-
Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.Haematologica. 2013 May;98(5):718-21. doi: 10.3324/haematol.2012.079129. Haematologica. 2013. PMID: 23633544 Free PMC article.
-
Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).Int J Med Sci. 2016 Jan 25;13(1):85-91. doi: 10.7150/ijms.10539. eCollection 2016. Int J Med Sci. 2016. PMID: 26917989 Free PMC article.
-
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.Blood Cancer J. 2015 Aug 14;5(8):e337. doi: 10.1038/bcj.2015.64. Blood Cancer J. 2015. PMID: 26832847 Free PMC article. Review.
Cited by
-
Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039. Haematologica. 2019. PMID: 31666340 Free PMC article. No abstract available.
-
Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis.Cells. 2021 Dec 24;11(1):49. doi: 10.3390/cells11010049. Cells. 2021. PMID: 35011611 Free PMC article.
-
Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK.EJHaem. 2022 Jun 29;3(3):785-793. doi: 10.1002/jha2.519. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051073 Free PMC article.
-
Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.Hematol Oncol Clin North Am. 2021 Apr;35(2):159-176. doi: 10.1016/j.hoc.2020.12.001. Epub 2021 Jan 26. Hematol Oncol Clin North Am. 2021. PMID: 33641861 Free PMC article. Review.
-
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.Am J Hematol. 2021 Nov 1;96(11):1472-1480. doi: 10.1002/ajh.26332. Epub 2021 Sep 6. Am J Hematol. 2021. PMID: 34424575 Free PMC article.
References
-
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092–1097. - PubMed
-
- Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia. 2014: 28(10):2092–2094. - PubMed
-
- Spivak JL. Myeloproliferative Neoplasms. N Engl J Med. 2017;377(9):895–896. - PubMed
-
- Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO Criteria for Diagnosis of Polycythemia Vera: A Prospective Analysis. Blood. 2013; 22(11):1881–1886. - PubMed
-
- Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Exp Rev Hematol. 2013;6(1):49–58. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources